MISSION® Predesigned siRNA were created using the proprietary Rosetta Inpharmatics siRNA Design algorithm in an exclusive partnership with Merck & Co. The Rosetta siRNA Design Algorithm utilizes Position-Specific Scoring Matrices and knowledge of the seed region to predict the most specific and effective sequences for your target genes. The algorithm’s rules were developed utilizing empirical data collected from gene silencing experiments carried out over three years.

Product Benefits

  • Best-in-class, guaranteed gene silencing
  • Efficient knockdown of low abundance messages
  • Simplified transfection optimization with 11 Positive Control siRNA
  • Distinguish sequence-specific silencing from non–specific effects with 8 negative control siRNA
  • Hundreds of functionally-validated predesigned siRNA

Product Features

  • Species: Human, Mouse & Rat
  • Quantities: 2 (10 nmol), 5 (25 nmol) & 10 (50 nmol) OD
  • Purification: Desalt or HPLC
  • Sequence Form: 21mer duplexes with dTdT overhangs
  • Modifications: 5' amine on sense strand
  • Quality Control: 100% mass spectrometry*
  • Format: Supplied dry in tubes

*Depending on manufacturing site, PAGE may be used to assess siRNA duplexes.

Product Pools

A popular pooled format is 4 duplexes at 5 nmol each combined into one tube (20 nmol pooled) plus the exact same 4 duplexes also at 5 nmol each in separate tubes (another 20 nmol individual). However, our sophisticated liquid handlers allow for a wide range of other possibilities. For feasibility review of your specific needs, contact sirnarequest@milliporesigma.

Validated siRNA

Many common gene targets have been validated for ≥75% mRNA knockdown (Figure 1 for example data and the table for a list of commonly-ordered, validated siRNA by gene symbol). Validated siRNA are suitable for transfection optimization and as positive controls.

HeLa cells transfected with predesigned siRNA at a concentration of 30 nM.

Figure 1.HeLa cells transfected with predesigned siRNA at a concentration of 30 nM. The percentage remaining gene expression levels were measured via qPCR 48 hours after transfection (relative to mock). Data represents the mean of four biological replicates.


Select Citations

Yang X, Sierant M, Janicka M, Peczek L, Martinez C, Hassell T, Li N, Li X, Wang T, Nawrot B. 2012. Gene Silencing Activity of siRNA Molecules Containing Phosphorodithioate Substitutions. ACS Chem. Biol.. 7(7):1214-1220. http://dx.doi.org/10.1021/cb300078e
Salma J, McDermott JC. 2012. Suppression of a MEF2-KLF6 Survival Pathway by PKA Signaling Promotes Apoptosis in Embryonic Hippocampal Neurons. Journal of Neuroscience. 32(8):2790-2803. http://dx.doi.org/10.1523/jneurosci.3609-11.2012
Gilot D, Le Meur N, Giudicelli F, Le Vée M, Lagadic-Gossmann D, Théret N, Fardel O. RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 Activity. PLoS ONE. 6(3):e18261. http://dx.doi.org/10.1371/journal.pone.0018261
Raab M, Kappel S, Krämer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T, et al. 2011. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun. 2(1): http://dx.doi.org/10.1038/ncomms1395
Chia KM, Liu J, Francis GD, Naderi A. 2011. A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer. Neoplasia. 13(2):154-166. http://dx.doi.org/10.1593/neo.101324
Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR Receptor Mediates the Effects of Adrenomedullin on Pancreatic Cancer Cells and on Cells of the Tumor Microenvironment. PLoS ONE. 4(10):e7502. http://dx.doi.org/10.1371/journal.pone.0007502
Santra MK, Wajapeyee N, Green MR. 2009. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 459(7247):722-725. http://dx.doi.org/10.1038/nature08011
Meng W, Mushika Y, Ichii T, Takeichi M. 2008. Anchorage of Microtubule Minus Ends to Adherens Junctions Regulates Epithelial Cell-Cell Contacts. Cell. 135(5):948-959. http://dx.doi.org/10.1016/j.cell.2008.09.040
Matsubara T, Kida K, Yamaguchi A, Hata K, Ichida F, Meguro H, Aburatani H, Nishimura R, Yoneda T. 2008. BMP2 Regulates Osterix through Msx2 and Runx2 during Osteoblast Differentiation. J. Biol. Chem.. 283(43):29119-29125. http://dx.doi.org/10.1074/jbc.m801774200
Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, et al. 2008. Genome-Scale RNAi Screen for Host Factors Required for HIV Replication. Cell Host & Microbe. 4(5):495-504. http://dx.doi.org/10.1016/j.chom.2008.10.004
Espeseth AS, Huang Q, Gates A, Xu M, Yu Y, Simon AJ, Shi X, Zhang X, Hodor P, Stone DJ, et al. 2006. A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels. Molecular and Cellular Neuroscience. 33(3):227-235. http://dx.doi.org/10.1016/j.mcn.2006.07.003
Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, et al. 2006. Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions. MCB. 26(24):9377-9386. http://dx.doi.org/10.1128/mcb.01229-06
Majercak J, Ray WJ, Espeseth A, Simon A, Shi X, Wolffe C, Getty K, Marine S, Stec E, Ferrer M, et al. 2006. LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proceedings of the National Academy of Sciences. 103(47):17967-17972. http://dx.doi.org/10.1073/pnas.0605461103

If additional help is needed, please consult our technical services group at oligotechserv@sial.com.

MISSION is a trademark of Merck KGaA, Darmstadt, Germany and/or its affiliates. Label License.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.